Health & Fitness
Tue, January 10, 2012Mon, January 9, 2012Sun, January 8, 2012Sat, January 7, 2012Fri, January 6, 2012Thu, January 5, 2012Wed, January 4, 2012Tue, January 3, 2012Mon, January 2, 2012Sat, December 31, 2011Fri, December 30, 2011Thu, December 29, 2011Wed, December 28, 2011Tue, December 27, 2011Mon, December 26, 2011Fri, December 23, 2011Keryx Biopharmaceuticals to Present at JP Morgan's 30th Annual Healthcare Conference
Published in Health and Fitness on Wednesday, January 4th 2012 at 5:38 GMT by Market Wire
Keryx Biopharmaceuticals to Present at JP Morgan's 30th Annual Healthcare Conference -- NEW YORK, Jan. 4, 2012 /PRNewswire/ --
Keryx Biopharmaceuticals to Present at JP Morgan's 30th Annual Healthcare Conference
Presentation Scheduled for Thursday, January 12th at 10:00 a.m. PT
NEW YORK, Jan. 4, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: [ KERX ]) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at JP Morgan's 30th Annual Healthcare Conference, being held January 9th-12th in San Francisco, California. Mr. Bentsur's presentation is scheduled to take place on Thursday, January 12, 2012 at 10:00 a.m. PT (1:00pm ET).
A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at [ http://investors.keryx.com ]. An archived version of the webcast will be available following the conclusion of the live presentation.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA). Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.
KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: [ lfischer@keryx.com ]
SOURCE Keryx Biopharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://investors.keryx.com ]
